Novo Nordisk's stock price dropped due to comments from U.S. President Donald Trump regarding potential price cuts for Ozempic, a drug used for diabetes and obesity. Trump suggested lowering the monthly price from approximately $1,000 to $150, which could significantly impact Novo Nordisk's revenue. The company is engaged in discussions with the administration about improving patient access and affordability.
